Arvinas (NASDAQ:ARVN) Releases Earnings Results, Beats Estimates By $0.06 EPS

Key Points

• Arvinas beat quarterly EPS estimates, reporting a loss of $0.82 per share versus the expected $0.88 loss. However, revenue fell 98.8% year over year to $0.50 million, far below the $16.93 million estimate.
• The company highlighted upcoming clinical milestones for ARV-393, ARV-027 and ARV-6723, while ARV-102 remains limited by an FDA clinical hold in the U.S.
• Arvinas ended the quarter with $558.9 million in cash and marketable securities, projecting funding into the second half of 2028. Shares traded near $6.98, while analysts maintained a “Moderate Buy” consensus with a $15.40 average price target.

Arvinas (NASDAQ:ARVN - Get Free Report) issued its quarterly earnings data on Tuesday. The company reported ($0.82) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.88) by $0.06, Zacks reports. Arvinas had a net margin of 2.94% and a return on equity of 1.91%. The company had revenue of $0.50 million for the quarter, compared to analyst estimates of $16.93 million. During the same period last year, the company posted ($0.48) earnings per share. Arvinas's revenue was down 98.8% compared to the same quarter last year.

Here are the key takeaways from Arvinas' conference call:

• ARV-393 is expected to deliver initial monotherapy data at ASH in December, focused on T-cell lymphoma, with additional B-cell lymphoma, durability, and glofitamab-combination data planned for mid-2027. Management said early responses have been observed across lymphoma subtypes and views the program as potentially competitive, though most initial patients were treated below predicted efficacious exposure levels.
• The company plans to dose SBMA patients with the oral ARV-027 androgen-receptor degrader in the first half of 2027, following healthy-volunteer data. Management is targeting approximately 50% reduction in polyQ-AR, which it believes could translate into improved muscle strength and endurance based on preclinical findings.
• ARV-6723, Arvinas’ oral HPK1 degrader, has entered a Phase I monotherapy trial, with pembrolizumab combination dosing planned for the first half of 2027 and initial clinical data expected in the second half of 2027. The company highlighted preclinical activity in checkpoint-resistant models and complete tumor regressions in combination studies, but clinical validation remains pending.
• Development of the LRRK2 degrader ARV-102 remains constrained by an ongoing FDA clinical hold in the U.S.; the company now expects to initiate a Phase Ib PSP trial in Europe and the U.K. in 2027 and may add U.S. sites later. While biomarker and oculomotor findings strengthened management’s confidence, the relationship between these measures and meaningful clinical benefit is not yet established.
• Arvinas ended the quarter with $558.9 million in cash, restricted cash, and marketable securities and projects funding into the second half of 2028. Lower year-over-year R&D and G&A spending supports the runway, although the balance declined from $685.4 million at year-end 2025 and some programs may extend beyond current cash guidance.

Arvinas Price Performance

ARVN traded down $0.54 on Tuesday, reaching $6.98. 242,653 shares of the company's stock were exchanged, compared to its average volume of 820,211. The stock has a market cap of $450.35 million, a PE ratio of 69.96 and a beta of 1.80. Arvinas has a twelve month low of $6.74 and a twelve month high of $14.51. The stock's fifty day moving average price is $8.06 and its 200-day moving average price is $9.68.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on the company. Morgan Stanley set a $10.00 price objective on Arvinas in a research report on Monday, August 10th. Weiss Ratings lowered shares of Arvinas from a "sell (d+)" rating to a "sell (d)" rating in a research report on Friday, October 23rd. Zacks Research upgraded shares of Arvinas from a "hold" rating to a "strong-buy" rating in a report on Friday, October 9th. Citigroup cut their price objective on shares of Arvinas from $24.00 to $21.00 and set a "buy" rating on the stock in a research report on Monday, August 10th. Finally, Evercore set a $14.00 price objective on shares of Arvinas in a research note on Monday, August 10th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $15.40.

Arvinas Company Profile

Arvinas, Inc is a clinical-stage biopharmaceutical company focused on developing medicines based on targeted protein degradation. The company's proprietary PROTAC® protein degrader platform is designed to direct the body's natural cellular machinery to selectively break down disease-causing proteins that may be difficult to address with conventional drug approaches.

Arvinas has concentrated its research and development efforts primarily on oncology, including hormone-driven cancers. Its pipeline has included vepdegestrant, an estrogen receptor protein degrader being developed for patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer, as well as other investigational degraders targeting cancer-related proteins.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.